Drug recall · August 24, 2022
Azacitidine for Injection recall
Why: Subpotent Drug
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Azacitidine for Injection, 100 mg Lyophilized Powder, Single-Dose Vials, Rx Only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 India. Manufactured for BluePoint Laboratories. NDC 68001-0313-56
- Lots / codes
Lot #: FE22001A, Exp. Date 01/2024
- Quantity
- 4,160 vials
- Company
- Amerisource Health Services LLC, Columbus, OH
- Distribution
- Nationwide within the USA
- Initiated
- July 27, 2022 · Voluntary: Firm initiated
- Classified
- August 17, 2022
- Reported
- August 24, 2022
- Ended
- September 28, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Azacitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.